Jeffrey Dunn, MD

Multiple sclerosis specialist

Clinical Professor, Neurology & Neurological Sciences

Multiple Sclerosis Center

  • 300 Pasteur Drive
  • Stanford, CA 94305
  • Phone: 650-723-6469
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Residency: University of Washington Medical Center (1993) WA

Internship: Eastern VA Medical School (1990) VA

Medical Education: Temple University School of Medicine (1989) PA

Board Certification: Neurology, American Board of Psychiatry and Neurology (1994)

Residency, University of Washington, Neurology (1993)

M.D., Temple University, Medicine (1989)

B.A., Haverford College, French Literature (1983)

Honors & Awards

Henry J. Kaiser Family Foundation Award for Excellence in Clinical Teaching, Stanford University School of Medicine (2013)

Top Doctors, US News & World Report (2012-2013)

AUPN Neurology national recuitment award, Association of University Professors of Neurology (2012)

Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine, Stanford University School of Medicine (2011)

Excellence in Teaching Award, Stanford University School of Medicine (2011-2012)

Excellence in Teaching Award, Stanford University School of Medicine (2010-2011)

AUPN Neurology Recruitment Award (highest percentage in U.S.), Association of University Professors of Neurology (2011)

Excellence in Neurology Clerkship Teaching Award, Stanford University Department of Neurology & Neurosciences (2008,2009,2010,2011,2012,2013)

Excellence in Teaching Award, Stanford University School of Medicine (2009-2010)

Lysia K. Forno Award for Excellence in Teaching Neurology Residents, Stanford University Department of Neurology & Neurosciences (2008-2009)

Fellow, American Academy of Neurology (2008-present)

"America's Top Rated Physicians", Guide to Top Doctors (1998-2007, 2010-2013)

Administrative Appointments

Co-Director, Stanford Multiple Sclerosis Center, 2008

Director, Neurology Clerkship Program, 2009

Chair, MS Education Workgroup, Multiple Sclerosis Section; American Academy of Neurology, 2011

Councilor, Executive Committee, Multiple Sclerosis Section; American Academy of Neurology, 2010

Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis
Lublin, F., & CombiRx Investigators. (2013). Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis. Annals of Neurology, 73(3).

Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein
Herges, K., de Jong, B. A., Kolkowitz, I., Dunn, C., Mandelbaum, G., & Axtell, R. C. (2012). Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. MULTIPLE SCLEROSIS JOURNAL, 18(4), 398-408.

Protective Effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin olidodendrocyte glycoprotein
Herges K, DeJong BA, Kolkowitz I, Dunn C, Mandelbaum G, & Axtell RC. (2012). Protective Effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin olidodendrocyte glycoprotein. Multiple Sclerosis, 18(4).

Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis
Dunn, J., & Blight, A. (2011). Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. CURRENT MEDICAL RESEARCH AND OPINION, 27(7), 1415-1423.

Dalfampridine: A brief review of its Mechanism of Action and Efficacy as a treatment to improve walking in patients with Multiple Sclerosis
Dunn J, & Blight A. (2011). Dalfampridine: A brief review of its Mechanism of Action and Efficacy as a treatment to improve walking in patients with Multiple Sclerosis. Current Research Medical Opinion, 27(7).

Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis
Dunn, J. (2010). Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 10(4), 433-440.

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., & Rose, J. W. (2010). Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. LANCET NEUROLOGY, 9(4), 381-390.

The impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis
Dunn, J. (2010). The impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. Expert Rev. Pharmacoeconomics Outcomes Res., 10(4).

Cytomegalovirus Infection with MRI Signal Abnormalities Affecting the Optic Nerves, Optic Chiasm, and Optic Tracts
Pershing, S., Dunn, J., Khan, A., & Liao, Y. J. (2009). Cytomegalovirus Infection with MRI Signal Abnormalities Affecting the Optic Nerves, Optic Chiasm, and Optic Tracts. JOURNAL OF NEURO-OPHTHALMOLOGY, 29(3), 223-226.

CMV Optic Neuritis with Extensive Tracking along the Visual Pathway
Pershing S, D. J. K. A. L. Jy. (2009). CMV Optic Neuritis with Extensive Tracking along the Visual Pathway. J Neuro-Ophthalmology, 29(3).

Glatiramer Acetate after Induction Therapy with Mitoxantrone in Relapsing Multiple Sclerosis
Vollmer T, P. H. B.-O. A. D. J. F. Ms. G. Sk. C. D. D. F. A. D. (2008). Glatiramer Acetate after Induction Therapy with Mitoxantrone in Relapsing Multiple Sclerosis. Multiple Sclerosis, Apr 18.

Tovaxin for Early Relapsing Multiple Sclerosis Phase 2b Placebo Controlled Trial of Autologous T cell vaccination in patients with CIS or RRMS
Fox, Ej., & The TERMS Study Investigators. (2008). Tovaxin for Early Relapsing Multiple Sclerosis Phase 2b Placebo Controlled Trial of Autologous T cell vaccination in patients with CIS or RRMS. Multiple Sclerosis, 14.

Glatiramer Acetate after Mitoxantrone Induction improves MRI markers of lesion volume and permanent tissue injury in MS
Arnold D., C. D. P. H. B.-O. A. D. J. F. M. G. S. K. V. T. (2008). Glatiramer Acetate after Mitoxantrone Induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol, 255.

Daclizumab in Patients with Active Relapsing Multiple Sclerosis on Concurrent Interferon beta Therapy; Week 24 data Phase II
Montalban X, K. M. W. D. et D. J. with the Choice. S. I. (2007). Daclizumab in Patients with Active Relapsing Multiple Sclerosis on Concurrent Interferon beta Therapy; Week 24 data Phase II. ECTRIMS, 10/11/07.

Randomized, Double Blind, Dose Comparison Study of Glatiramer Acetate in Relapsing Remitting MS
Cohen JA Rovaris M Goodman AD Ladkani D Wynn D Filippi M 9006 Study Group. (2007). Randomized, Double Blind, Dose Comparison Study of Glatiramer Acetate in Relapsing Remitting MS. Neurology, 68(12).

Safety and Tolerability of Glatiramer Acetate in Pediatric Patients with Relapsing Remitting Multiple Sclerosis
Krupp L, B. B. P. M. D. J. W.-G. B. P. L. (2005). Safety and Tolerability of Glatiramer Acetate in Pediatric Patients with Relapsing Remitting Multiple Sclerosis. ECTRIMS/ACTRIMS, (September).

Comprehensive Outpatient Management of Patients with Multiple Sclerosis
Odderson I, D. J. (2001). Comprehensive Outpatient Management of Patients with Multiple Sclerosis. RIMS MS Symposium, (May).

Novantrone in the Treatment of Multiple Sclerosis
Dunn Jeffrey, K. M. L. S. B. J. (2001). Novantrone in the Treatment of Multiple Sclerosis. Alliance News.

Clinical Advisory Committee Statement
Bowen J., D. J. E. K. G. H. R. G. S. J. S. C. T. L. (1999). Clinical Advisory Committee Statement. Health Care Connection, I(1).

Gingko Biloba in the Treatment of Alzheimer's Disease
Dunn Jeffrey E., M. R. P. J. (1998). Gingko Biloba in the Treatment of Alzheimer's Disease. Alternative Medicine, 1(15).

Atherosclerotic Aortic Disease as a Source of Embolic Infarct
Bursell John P., O. I. D. J. E. (1996). Atherosclerotic Aortic Disease as a Source of Embolic Infarct. Journal of Neurovascular Disease, 1(2).

INTRACEREBRAL BACILLARY ANGIOMATOSIS IN A PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
Spach, D. H., Panther, L. A., Thorning, D. R., Dunn, J. E., Plorde, J. J., & MILLER, R. A. (1992). INTRACEREBRAL BACILLARY ANGIOMATOSIS IN A PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS. ANNALS OF INTERNAL MEDICINE, 116(9), 740-742.

Intracerebral Bacillary Angiomatosis in a Patient Infected with HIV
Spach, D., Panther L., Thorning D., Dunn Jeffrey E., Plorde J.L., & R. (1992). Intracerebral Bacillary Angiomatosis in a Patient Infected with HIV. Annals of Internal Medicine, 116.